Key facts
- 100XBio’s last known valuation is $8.0M (Apr 2025).
- It has raised $480K; the latest was Seed Round ($50K) in Apr 2025.
- Notable investors include Bioincubator, C2I Accelerator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for 100XBio
- ·The full record, as it builds
Funding rounds
No funding rounds for 100XBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 100XBio
Operator of a biotechnology company intended to offer efficient T-cell research. The company develops innovative approaches to streamline the analysis of T-cell antigen specificity and sequencing, enabling researchers and clinicians to understand the diversity and specificity of the receptors, which is important for various aspects of immunology, immunotherapy, and disease diagnosis and treatment.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2023
- Employees
- 2
- Website
- 100xbio.com/
- Ownership
- Privately Held (backing)
100XBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 100XBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 100XBio in its N-PORT filings yet. We sweep new filings monthly.